Research advances of immune checkpoint inhibitors in the treatment of cholangiocarcinoma / 中华消化外科杂志

ABSTRACT

Cholangiocarcinoma is a rarely malignant tumor with poor overall prognosis. Radical surgery is the only strategy to improve the long-term survival of patients with cholangio-carcinoma of early-stage. For most patients with advanced cholangiocarcinoma, systematic treatment has become the main strategy. But the available first-line drugs for the treatment of cholangiocarcinoma are limited and the curative effect is limited. In recent years, immunotherapy strategies such as immune checkpoint inhibitors have achieved encouraging results in a variety of solid tumors by using the host immune system to carry out effective anti-tumor responses. The authors summarize the research advances of immune checkpoint inhibitors in the treatment of cholangiocarcinoma.